Takeda Pharmaceutical Company (TAK) has released an update.
Takeda Pharmaceutical Company Limited has announced the issuance of its 2nd Hybrid Bonds, a strategic financial move aimed at refinancing its 1st Hybrid Bonds issued in 2019. These new bonds blend debt and equity features, including long maturities of up to 60 years and an equity acknowledgement of 50% from rating agencies, although they are not convertible to equity. The pricing and issuance of these bonds are scheduled for mid-2024, depending on market conditions and investor interest.
For further insights into TAK stock, check out TipRanks’ Stock Analysis page.
